Archive

Bolagsnyheter

BioStock: Cyxone focuses on the RA programme

First North-listed Cyxone recently published its Q1 report, a period during which the company carried out a rights issue of 61 MSEK, and advanced the company's drug candidates rabeximod...
Mangold Insight